Evidence map›Paper›PMID 41917621›Full record

ArticleDiscover oncology2026

Collagen type I alpha 2 acts as a potential diagnostic biomarker and therapeutic targets for the prognosis in gastric cancer.

Jingjing Dai, Xudong Song, Abdusemer Reyimu, Zihao Gao, Chenggong Zhang, Fan Ding, Dezhu Dai, Liang Shi, Xiao Han, Wubi Zhou and 1 more

Abstract read
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jingjing Dai *Department of Medical Laboratory, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China.
Xudong Song *Department of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China.
Abdusemer Reyimu *Department of Pathology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China.
Zihao GaoDepartment of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China.
Chenggong ZhangDepartment of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China.
Fan DingDepartment of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China.
Dezhu DaiDepartment of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China.
Liang ShiDepartment of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China.
Xiao HanDepartment of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China. 178268875@163.com.
Wubi ZhouDepartment of Pathology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China. hayyzhouwubi@njmu.edu.cn.
Guoquan TaoDepartment of Gastrointestinal Surgery, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, People's Republic of China. taoguoquan5698102@163.com.

Funding

the National Natural Science Foundation of China 81773538The Sixth "333 Project" Talent Support Special Fund of Jiangsu Province S333YQ002the Special Fund for the Jiangsu Provincial Medical Key Discipline Cultivation Unit in China JSDW202233
6 · The paper itself

Abstract

backgroundGastric cancer (GC) is a common digestive tract cancer whose high heterogeneity and invasiveness lead to a low survival rate. Therefore, it is necessary to explore the potential molecular mechanism of GC.

methodsThree genes and one miRNA expression microarray dataset were downloaded from the GEO database. The gene expression profiles of the cancer group and normal group were compared in each dataset, and differentially expressed genes (DEGs) and miRNAs were identified with GEO2R. GO enrichment and KEGG pathway analysis of DEGs were performed with the R package clusterProfiler. The interaction network of DEGs was visualized with Cytoscape, and clusters and key genes were identified. According to the key DEGs, a prognostic risk model of GC was established by Cox regression. The patients were subdivided into high-risk and low-risk groups based on the median value of the risk score, and the model performance was evaluated by ROC curve and survival analyses. The risk model was combined with clinicopathological features to establish a nomogram, and a calibration chart was used to evaluate the prediction accuracy of the nomogram. The ROC curve was drawn to predict the ability of genes to differentiate tumour tissues from normal tissues. The starBase database was used to construct a regulatory network consistent with the miRNA-mRNA hypothesis. The expression of COL1A2 was analysed by immunohistochemistry/immunocytochemistry (IHC/ICC) in 150 patients with gastric cancer and a GC cell line. The correlations between COL1A2 expression and clinical features were analysed.

resultsA total of 106 DEGs and 113 differentially expressed miRNAs were identified from the gastric cancer dataset. PPI network screening revealed the two most significant modules and identified the dominant gene. A prognostic risk model composed of six prognostic genes (COL1A2, COL1A1, COL3A1, SPARC, LUM and BGN) was constructed by Cox regression analysis. The prognosis of the high-risk group was poor (P < 0.001). ROC curve analysis (AUC = 0.732) showed that the model better predicted the 5-year survival rate of patients. In addition, the six prognostic genes had appropriate diagnostic ability for GC. A potential ceRNA network of model genes in GC was constructed through the starBase database. IHC showed that COL1A2 was highly expressed in gastric cancer and GC cells. COL1A2 expression was significantly correlated with lymph node metastasis.

conclusionThis study reveals the potential biomarkers and related pathways of GC and provides a theoretical basis for the diagnosis and prognosis prediction of GC.

Indexed as

Bioinformatics analysisClinical parametersCOL1A2Gastric cancerPrognosis

Identifiers

PMID41917621
PMCPMC13168407

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.